Nuformix plc (LON:NFX – Get Free Report)’s share price hit a new 52-week low on Wednesday. The company traded as low as GBX 0.09 and last traded at GBX 0.10, with a volume of 106,824,398 shares traded. The stock had previously closed at GBX 0.10.
Nuformix Trading Down 1.1%
The stock has a market capitalization of £2.45 million, a P/E ratio of -3.21 and a beta of 1.53. The company has a 50-day moving average price of GBX 0.13 and a two-hundred day moving average price of GBX 0.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Articles
- Five stocks we like better than Nuformix
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
